Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

BRS - Year 2 > 🫀🫁Cardio & Resp🫀🫁 - Lung Cancer > Flashcards

🫀🫁Cardio & Resp🫀🫁 - Lung Cancer Flashcards

1
Q

What are the key epidemiological facts about lung cancer?

A

3rd most common cancer in the UK
48000 diagnoses/year
35000 deaths/year
Leading cause of cancer death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What groups of people are statistically more likely to get lung cancer?

A

Peak age 75-90
Males>females
Lower socioeconomic status
Smoking history strong indicator - duration, intensity, when stopped
Despite this, 10-15% patients with lung cancer never smoked

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What other causes are there for lung cancer, other than smoking?

A

Asbestos - exposure associated with up to 2x risk
Radon - historically mining
Indoor cooking fumes
Chronic lung diseases
Air pollution
Fx/genetic factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the basic pathogenesis of lung cancer?

A

Lung cancer may arise from all differentiated and undifferentiated cells
Interaction between inhaled carcinogens and epithelium of upper and lower airways - leads to the formation of DNA adducts - pieces of DNA covalently bound to a cancer-causing chemical
Persisting/misrepaired adducts result in mutations - cause genomic alterations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the various pathophysiologies of lung cancer?

A
  1. Squamous cell carcinoma (~30% of cases)
  2. Adenocarcinoma (~40%)
  3. Large cell lung cancer (~15%)
  4. Small cell lung cancer (~15%)
    1-3 often grouped together as non-small cell lung cancer (NSCLC)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Outline squamous cell carcinoma lung cancer

A

30% of cases
Previously the most common
Originating from the bronchial epithelium - centrally located
(Coughing, haemoptysis, recurrent infections due to airway obstruction)
(Moderately fast - slower than small cell but can invade nearby structures early - better prognosis than small cell but worse than adenocarcinoma)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Outline adenocarcinoma lung cancer

A

40% of cases
Most common from 1980s onwards
Originates from mucus-producing glandular tissue- more peripheral
Accounts for most non-smoking lung cancer cases
(Later presentation with vague symptoms like shortness of breath/chest pain)
(Slower growing, can metastasize early, especially to bones and brain - generally better prognosis, especially if detected early)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Outline large cell lung cancer

A

15% of cases
Heterogenous group, undifferentiated
Often peripheral, but can be anywhere
(Non-specific symptoms; can cause chest pain, cough, or symptoms based on where it spreads)
(Aggressive, rapid growth, high likelihood of metastasis.
Poor prognosis due to rapid progression and late detection)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Outline small cell lung cancer

A

15% of cases
Originate from pulmonary neuroendocrine cells
Highly malignant
(Rapid onset of cough, weight loss, and paraneoplastic syndromes (e.g., SIADH, Cushing syndrome))
(Very fast growing, early and widespread metastasis.
Poorest prognosis, high recurrence rate even with treatment)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Name the 4 most important oncogenes in the pathogenesis of lung cancer, specifically mutations in them

A

Epidermal growth factor receptor (EGFR) tyrosine kinase
Anaplastic lymphoma kinase (ALK) tyrosine kinase
c-ROS oncogene 1 (ROS1) receptor tyrosine kinase
BRAF (downstream cell-cycle signalling mediator)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the significance of an Epidermal growth factor receptor (EGFR) tyrosine kinase mutation?

A

15-30% of adenocarcinoma
More so in women, Asian ethnicity, never-smokers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the significance of an Anaplastic lymphoma kinase (ALK) tyrosine kinase mutation?

A

2-7% of non-small cell lung cancer
Especially in younger patients and never-smokers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the significance in a c-ROS oncogene 1 (ROS1) receptor tyrosine kinase mutation?

A

1-2% of non-small cell lung cancer
Especially in younger patients and never-smoker

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the significance of a BRAF (downstream cell-cycle signalling mediator) mutation?

A

1-3% of non-small cell lung cancer
Especially in smokers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the key symptoms of lung cancer?

A

Cough
Weight loss
Breathlessness
Fatigue
Chest pain
Haemoptysis
Can be frequently asymptomatic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the key features of advanced/metastatic lung cancer?

A

Neurological features:
Focal weakness, seizures, spinal cord compression
Bone pain
Paraneoplastic syndromes:
Clubbing, hypercalcaemia, hyponatraemia, Cushing’s

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is clubbing?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is cachexia

A

Severe, rapid muscle loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is Pemberton’s sign?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What is Horner’s syndrome?

A

Decreased pupil size, a drooping eyelid and decreased sweating on the affected side of the face

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is the diagnostic strategy for suspected lung cancer?

A

Establish most likely diagnosis
Establish fitness for investigation and treatment
Confirm diagnosis and histological type
-genomic testing key if considering systemic treatment in NSCLC
Confirm staging

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Who is in the lung cancer MDT?

A

Respiratory doctor
Radiologist
Pathology doctor
Thoracic surgeon
Oncologist
Palliative care
(Patient)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Who is currently eligible for lung cancer screening?

A

Current or ex-smokers aged between 55 and 74 are invited via their GP to attend a lung health check
Offered an appointment for a low dose CT scan
RMP pilot: Lung cancer detected in 29/1145 (2.5 %) participants scanned (stage 1, 58.6 %)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

How is PET-CT useful?

A

Helps exclude occult metastases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What are occult metastases?

A

Metastatic cancer cells that have spread from the primary tumour site but are too small to be detected with conventional imaging techniques or during physical examination

26
Q

How do you choose a method of biopsy for lung cancers?

A

Choose method based on accessibility, availability and impact on staging

27
Q

What would you use a bronchoscopy for?

A

Tumours of central and segmental airways

28
Q

How would you stage the mediastinum +/- achieve tissue diagnosis?

A

Endobronchial ultrasound and transbronchial-needle aspiration of mediastinal lymph nodes (EBUS [TBNA])

29
Q

When would you use navigational bronchoscopy + robotic Bronchoscopy?

A

For peripheral lesions/nodules that are not amenable to conventional bronchoscopy or CT guided biopsy

30
Q

How are biopsies taken from peripheral lung tumours?

A

CT-guided lung biopsy

31
Q

How are lung cancers staged?

A

T1-4: tumour size and location
N0-3: lymph node involvement – mediastinum + beyond
M0-1c: metastases + number

32
Q

Describe what you would see in early vs locally-advanced vs metastatic

A
33
Q

What 5 factors act as determinants of treatment for lung cancer?

A

Patient fitness
Cancer histology
Cancer stage
Patient preference
Health service factors

34
Q

What is the WHO performance status?

A

Scale that measures patient fitness
0 - Asymptomatic
1- Symptomatic but completely ambulatory
2 - Symptomatic, up and about >50% of waking hours
3 - Symptomatic, confined to bed or chair >50% of waking hours
4 - Completely disabled
5 - Death
Radical treatment usually restricted to PS 0-2

35
Q

What is meant by “asymptomatic” on the WHO performance status?

A

Fully active, able to carry on all predisease activities without restriction

36
Q

What is meant by “symptomatic but completely ambulatory” on the WHO performance status?

A

Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature. For example, light housework, office work

37
Q

What is meant by “symptomatic, up and about >50% of waking hours” on the WHO performance status?

A

Ambulatory and capable of all self care but unable to carry out any work activities

38
Q

What is meant by “symptomatic, confined to bed or chair >50% of waking hours” on the WHO performance status?

A

Capable of only limited self-care

39
Q

What is meant by “completely disabled” on the WHO performance status?

A

Completely disabled. Cannot carry on any self-care
Totally confined to bed or chair

40
Q

What is meant by “death” on the WHO performance status?

A

Take a wild guess

41
Q

What must also be considered when assessing a patient’s WHO performance status?

A

Comorbidity + lung function also very important

42
Q

What is the standard care for early stage disease?

A

Surgical resection is standard of care for early stage disease
Lobectomy + lymphadenectomy usual approach
Sublobar resection if stage 1 (≤3 𝑐𝑚)

43
Q

What is an alternative to surgery in early stage disease?

A

Radical radiotherapy
Particularly relevant if there is a comorbidity
Stereotactic ablative body radiotherapy (SABR)
Technique of choice
High-precision targeting, multiple convergent beams

44
Q

What are the systemic treatments available for lung cancer treatment

A

Oncogene-directed drugs
Immunotherapy
Cytotoxic chemotherapy

45
Q

When are systemic treatments used to treat lung cancers?

A

First line for metastatic NSCLC with mutation

46
Q

What are the NICE approved drugs for use in oncogene-directed therapy?

A

EGFR: erlotinib, gefitinib, afatinib, dacomitinib, and osimertinib
ALK: crizotinib, ceritinib, alectinib, brigatinib, lorlatinib
ROS-1: crizotinib, entrectinib

47
Q

What is the reported efficacy of oncogene-directed therapy?

A

Improvements in progression-free survival, modest overall survival vs standard chemotherapy

48
Q

What side effects can be experienced in oncogene-directed systemic treatment?

A

Generally well-tolerated (tablets)
Rash, diarrhoea, and (uncommonly) pneumonitis

49
Q

When is immunotherapy used to treat lung cancer?

A

First line for metastatic NSCLC with no mutation (and PDL1 ≥50%)

50
Q

What are the NICE approved immunotherapy drugs?

A

Pembrolizumab, atezolizumab, nivolumab

51
Q

How does immunotherapy help treat lung cancer?

A
52
Q

What is the reported efficacy of immunotherapy in treating lung cancer?

A

Improvements in progression-free survival AND overall survival vs standard chemotherapy

53
Q

What are the potential side effects of immunotherapy?

A

Generally well-tolerated
Immune-related side-effects in 10-15% (thyroid, skin, bowel, lung, liver)

54
Q

When is cytotoxic chemotherapy used to treat lung cancer?

A

First line for metastatic NSCLC with no mutation and PDL1 ≤50% (in combination with immunotherapy)

55
Q

Outline the function of cytotoxic chemotherapy

A

Long established
Target any rapidly dividing cells
Platinum-based regimens, e.g. carboplatin, cisplatin, paclitaxel, pemetrexed

56
Q

What is the reported efficacy of cytotoxic chemotherapy?

A

When used alone (old data, pre-2000) - modest improvements in overall survival vs best supportive care:
e.g. 29 vs 20% one year survival in clinical trials
With pembrolizumab, a lot better (23% 2y survival vs 5% for standard chemo alone)

57
Q

What are the potential side effects of cytotoxic chemotherapy?

A

Frequent: fatigue, nausea, bone marrow suppression, nephrotoxicity
Quality of life poorly evaluated in trials; no evidence for improvement

58
Q

When does palliative and supportive care become relevant?

A

Should be offered as standard to all patients with advanced stage disease

59
Q

What is the aim of palliative and supportive care?

A

Symptom control, psychological support, education, practical/financial support, planning for end of life
Lung cancer specialist nurses key

60
Q

What is the evidence that supports palliative care?

A

Evidence for survival as well as symptomatic benefit:
151 patients, new diagnosis NSCLC in USA
Standard oncology care +/- early palliative care
At 12 weeks:
-Improved quality of life
-Lower depression scores
-Median survival 11.6 v 8.9 months

61
Q

Give a summary of lung cancer treatment

A
62
Q

What is the general prognosis for lung cancer?

A

Only 10% live >10 years
Little change in survival in last 40 years (BUT this may be now out of date)

BRS - Year 2 (46 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions